To date, attempts to modulate these immunoregulatory pathways have been centered around TIGIT antagonism and/or CD226 agonism in the context of cancer immunotherapy utilizing antibodies, with mixed results being observed in clinical trials17,18. This evidence concerns the gene TIGIT and cancer.